CSF3 and Decreased total neutrophil count: Since cost-savings associated with biosimilars has implications for increasing access to G-CSF supportive care, it is important to characterise the subset of patients at 10% to 20% risk of neutropenia who are most likely to benefit from G-CSF prophylaxis.